SuperworthPenumbra EPS PEN
Diluted earnings per share by quarter and over the last twelve months, from 2014.
- Last 12 months, to Jun 30, 2026
- $4.07
- Latest quarter, Q2 FY26
- $0.88
- −23% on a year earlier
- Fiscal year 2025
- $4.52
- +1229% on the year before
Penumbra's earnings per share was $4.07 over the twelve months to Jun 30, 2026, up 8% on a year earlier.
In its latest quarter, Q2 FY26, it was $0.88, down 23% on the same quarter a year before.
Earnings per share over time
Fiscal year by fiscal year
| Fiscal year | EPS | Change |
|---|---|---|
| FY2025 | $4.52 | +1229% |
| FY2024 | $0.34 | −85% |
| FY2023 | $2.31 | n/a |
| FY2022 | −$0.06 | −140% |
| FY2021 | $0.15 | n/a |
| FY2020 | −$0.44 | −133% |
| FY2019 | $1.35 | +800% |
| FY2018 | $0.15 | +36% |
| FY2017 | $0.11 | −74% |
| FY2016 | $0.43 | +975% |
| FY2015 | $0.04 | n/a |
| FY2014 | −$0.19 | n/a |
Each fiscal year is the twelve months to its fourth quarter.
Quarter by quarter
| Quarter | Ended | EPS | On a year earlier | Last 12 months |
|---|---|---|---|---|
| Q2 FY26 | $0.88 | −23% | $4.07 | |
| Q1 FY26 | $0.82 | −18% | $4.34 | |
| Q4 FY25 | $1.20 | +40% | $4.52 | |
| Q3 FY25 | $1.17 | +56% | $4.18 | |
| Q2 FY25 | $1.15 | n/a | $3.76 | |
| Q1 FY25 | $1.00 | +257% | $1.06 | |
| Q4 FY24 | $0.86 | −38% | $0.34 | |
| Q3 FY24 | $0.75 | +226% | $0.86 | |
| Q2 FY24 | −$1.55 | −423% | $0.34 | |
| Q1 FY24 | $0.28 | +27% | $2.37 | |
| Q4 FY23 | $1.38 | +1280% | $2.31 | |
| Q3 FY23 | $0.23 | n/a | $1.03 |
Against its peers
Companies in Medical - Instruments & Supplies nearest Penumbra's size, closest first, today.
| Company | EPS, 12 months | Growth |
|---|---|---|
| PENPenumbra | $4.07 | +8% a year |
| COOCooper Companies | $2.93 | +44% a year |
| SOLVSolventum | $8.18 | +277% a year |
| ALGNAlign Technology | $5.75 | −3% a year |
| GMEDGlobus Medical | $3.91 | +50% a year |
| PODDInsulet | $5.35 | +64% a year |
| MSAMSA Safety | $8.04 | +15% a year |
| WSTWest Pharmaceutical Services | $7.81 | +17% a year |
| MMSIMerit Medical Systems | $2.42 | +23% a year |
| HAEHaemonetics | $2.04 | −38% a year |
| VNTVontier | $2.41 | −8% a year |
| Peer median | $4.63 |
Where Penumbra ranks
What the EPS figure tells you
Net income divided by diluted shares. The denominator of PE.
One-off charges and gains swing it. The TTM view smooths a single odd quarter.
More on Penumbra
Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.